CA2432111A1 - Proteine jfy induisant l'apoptose rapide - Google Patents

Proteine jfy induisant l'apoptose rapide Download PDF

Info

Publication number
CA2432111A1
CA2432111A1 CA002432111A CA2432111A CA2432111A1 CA 2432111 A1 CA2432111 A1 CA 2432111A1 CA 002432111 A CA002432111 A CA 002432111A CA 2432111 A CA2432111 A CA 2432111A CA 2432111 A1 CA2432111 A1 CA 2432111A1
Authority
CA
Canada
Prior art keywords
jfy1
seq
expression
isolated
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002432111A
Other languages
English (en)
Inventor
Jian Yu
Kenneth W. Kinzler
Bert Vogelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2432111A1 publication Critical patent/CA2432111A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Selon l'invention, la caractérisation globale des gènes exprimés immédiatement après l'expression de p53 a permis d'identifier un gène appelé <I>JFY1</I>. La protéine codée par <I>JFY1</I> s'est avérée être exclusivement mitochondriale et se lier à Bcl-2 et Bcl-X¿L? par le biais d'un domaine BH3. L'expression exogène de <I>JFY1</I> a résulté en une apoptose extrêmement rapide et profonde survenant bien avant celle résultant de l'expression exogène de p53. Sur la base de ses seuls motifs d'expression, de la dépendance à p-53 et des propriétés biochimiques, JFY1 est probablement un médiateur direct de l'apoptose associée à p53.
CA002432111A 2000-12-19 2001-12-12 Proteine jfy induisant l'apoptose rapide Abandoned CA2432111A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25632800P 2000-12-19 2000-12-19
US60/256,328 2000-12-19
PCT/US2001/047455 WO2002064790A2 (fr) 2000-12-19 2001-12-12 Proteine jfy induisant l'apoptose rapide

Publications (1)

Publication Number Publication Date
CA2432111A1 true CA2432111A1 (fr) 2002-08-22

Family

ID=22971833

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002432111A Abandoned CA2432111A1 (fr) 2000-12-19 2001-12-12 Proteine jfy induisant l'apoptose rapide

Country Status (4)

Country Link
EP (1) EP1343884A2 (fr)
JP (1) JP2004530422A (fr)
CA (1) CA2432111A1 (fr)
WO (1) WO2002064790A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US7202024B2 (en) 2001-09-17 2007-04-10 Immunogen Inc. bbc3 Gene promoter and methods for identifying modulators of apoptosis and bbc3 gene expression using a bbc3 gene promoter
CA2544223C (fr) 2003-11-05 2017-03-07 Dana-Farber Cancer Institute, Inc. Peptides alpha-helicoidaux stabilises et leurs applications
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
CN104474529A (zh) 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US20110144306A1 (en) 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
EP2342221B1 (fr) 2008-09-22 2018-11-07 Aileron Therapeutics, Inc. Procédés pour préparer des compositions de polypeptide purifié
WO2010083347A2 (fr) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques
WO2011008260A2 (fr) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Peptides bifonctionnels insérés et leurs utilisations
WO2011038049A1 (fr) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
JP2013535514A (ja) 2010-08-13 2013-09-12 エイルロン セラピューティクス，インコーポレイテッド ペプチド模倣大環状分子
WO2012040459A2 (fr) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Peptides de ciblage de la béta-caténine et leurs utilisations
WO2012174423A1 (fr) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Polypeptides stabilisés comme régulateurs de fonction gtpase rab
JP6342808B2 (ja) 2011-10-18 2018-06-13 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
AU2013221433B2 (en) 2012-02-15 2018-01-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
PT2920197T (pt) 2012-09-26 2021-06-11 Harvard College Péptidos agrafados com bloqueio de prolina e suas utilizações
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
EP3391898A3 (fr) 2013-03-13 2019-02-13 President and Fellows of Harvard College Polypeptides piqués et agrafés et leurs utilisations
JP2016523241A (ja) 2013-06-14 2016-08-08 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化されたポリペプチドインスリン受容体調節剤
JP6759109B2 (ja) 2014-05-21 2020-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｒａｓ抑制性ペプチドおよびその使用
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
CA2979847A1 (fr) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques et leurs utilisations
JP6622007B2 (ja) * 2015-05-29 2019-12-18 オリンパス株式会社 細胞評価方法
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129102A1 (fr) * 1998-11-02 2001-09-05 Clontech Laboratories Inc. Gene et proteine regulant la mort cellulaire

Also Published As

Publication number Publication date
WO2002064790A3 (fr) 2003-05-30
JP2004530422A (ja) 2004-10-07
WO2002064790A2 (fr) 2002-08-22
EP1343884A2 (fr) 2003-09-17

Similar Documents

Publication Publication Date Title
CA2432111A1 (fr) Proteine jfy induisant l&#39;apoptose rapide
Yu et al. PUMA induces the rapid apoptosis of colorectal cancer cells
US5863795A (en) Nucleic acids that encode peptides which modulate apoptosis
JP2001502894A (ja) ドメイン死アゴニストと相互作用するｂｈ３
US20080220455A1 (en) p53-DEPENDENT APOPTOSIS-INDUCING PROTEIN AND METHOD OF SCREENING FOR APOPTOSIS REGULATOR
JP2010233569A (ja) アポトーシスを調節する方法および組成物
US20040146971A1 (en) Novel p53 inducible protein
KR20010022741A (ko) 신규 노화-인자 유전자, ｐ23의 단리
US20040228866A1 (en) Suppressor genes
WO1998040397A1 (fr) Proteines inhibitrices de bax
JP2006524508A (ja) 骨関連の活性を調節する新規な方法
US7053194B2 (en) Compositions and methods for p53-mediated repression of gene expression
AU2004223739B2 (en) Cyclic AMP response element activator proteins and uses related thereto
US20050220781A1 (en) IFIX, a novel HIN-200 protein, for cancer therapy
US20040077832A1 (en) Jfy1protein induces rapid apoptosis
AU2002253804A1 (en) JFY1 protein induces rapid apoptosis
US20040241797A1 (en) Use of alphacp1, alphacp2, and hur for modulating gene expression and inducing angiogenesis
JP2000511781A (ja) アポトーシスを調節する方法および試薬
WO2000026634A2 (fr) Compositions et procedes permettant l&#39;identification d&#39;agents inhibant les signaux anti-apoptotiques transmis par mapk
JP2002541760A (ja) ｃ−ｍｙｃはβ−カテニンおよびＴＣＦ−４によって活性化される
US20030022837A1 (en) Modulation of cell division by an early mitotic inhibitor protein
JP2005526485A (ja) ｂｂｃ３遺伝子プロモーターならびにｂｂｃ３遺伝子プロモーターを用いてアポトーシスおよびｂｂｃ３遺伝子発現のモジュレーターを同定する方法
US20030073236A1 (en) p193 proteins and nucleic acids, and uses thereof
US7396669B2 (en) Mammalian endonucleases and methods of use
JP4280878B2 (ja) Ｍａｓｌ１遺伝子

Legal Events

Date Code Title Description
FZDE Dead